Brokerage firm Roth Capital Terminates its rating on Omeros Corporation(NASDAQ:OMER). In a research note issued to the investors, the brokerage major Removes the price-target to $ per share. Previously, the analysts had a Buy rating on the shares. The rating by Roth Capital was issued on Apr 12, 2016.
Omeros Corporation (OMER) shares turned negative on Fridays trading session with the shares closing down -0.23 points or -1.50% at a volume of 4,18,368. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $15.31. The peak price level was also seen at $15.31 while the days lowest was $14.99. Finally the shares closed at $15.07. The 52-week high of the shares is $30.23 while the 52-week low is $8.9. According to the latest information available, the market cap of the company is $577 M.
Omeros Corporation(OMER) last announced its earnings results on Mar 8, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $6.67M. Analysts had an estimated revenue of $5.35M. Earnings per share were $-0.42. Analysts had estimated an EPS of $-0.55.
Several Insider Transactions has been reported to the SEC. On Mar 17, 2016, Marcia S. Kelbon (VP Patent and General Counsel) sold 15,900 shares at $15.12 per share price.Also, On Nov 20, 2015, Thomas J. Cable (director) sold 2,000 shares at $13.73 per share price.On Sep 8, 2015, Peter A Md Demopulos (director) purchased 3,962 shares at $12.68 per share price, according to the Form-4 filing with the securities and exchange commission.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL) which is replacement surgery to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omidria is derived from its PharmacoSurgery platform which is for patients undergoing ophthalmological arthroscopic urological and other surgical procedures. It also has six clinical-stage development programs in its pipeline which includes a group of preclinical programs as well as two additional platforms: one capable of unlocking new G protein-coupled receptor drug targets and the other used to generate antibodies.